Fusion Pharmaceuticals (FUSN)
(Delayed Data from NSDQ)
$21.40 USD
0.00 (0.00%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $21.36 -0.04 (-0.19%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for Fusion Pharmaceuticals Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2 | 1 | 1 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 2 | 1 | 1 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 101 | 90 | 83 | 38 | 18 |
Income After Depreciation & Amortization | -99 | -88 | -82 | -38 | -18 |
Non-Operating Income | 5 | -1 | 1 | -38 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -94 | -89 | -81 | -76 | -16 |
Income Taxes | 1 | -2 | 0 | 3 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -95 | -88 | -81 | -78 | -16 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -95 | -88 | -81 | -78 | -16 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -98 | -87 | -81 | -37 | -18 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -99 | -88 | -82 | -38 | -18 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 65.61 | 43.75 | 42.60 | 22.03 | NA |
Diluted EPS Before Non-Recurring Items | -1.45 | -2.00 | -1.90 | -1.84 | NA |
Diluted Net EPS (GAAP) | -1.45 | -2.00 | -1.90 | -3.62 | -8.45 |
Fiscal Year end for Fusion Pharmaceuticals Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 2.01 | 0.03 | 0.03 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 2.01 | 0.03 | 0.03 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 28.28 | 21.40 | 26.74 | 24.89 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -28.28 | -19.39 | -26.71 | -24.86 |
Non-Operating Income | NA | 1.39 | 1.88 | 1.29 | 0.55 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -26.88 | -17.51 | -25.42 | -24.30 |
Income Taxes | NA | 1.30 | -0.25 | -0.25 | -0.01 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -28.18 | -17.25 | -25.18 | -24.29 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -28.18 | -17.25 | -25.18 | -24.29 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 73.09 | 69.05 | 66.28 | 53.78 |
Diluted EPS Before Non-Recurring Items | NA | -0.39 | -0.25 | -0.38 | -0.45 |
Diluted Net EPS (GAAP) | NA | -0.37 | -0.25 | -0.38 | -0.45 |